News
The Role of Therapy in Managing Chronic Stress and Trauma
Have you ever felt like you’re constantly tired, even after a full night’s sleep? Like your mind is always racing, your shoulders are always tense, and peace feels more like a rumor than a reality? If so, you’re not...
News
Is Social Work the Right Career for You? Key Skills and Values
If you have ever felt pulled toward a career where you help people through real challenges, social work may be on your mind. Many people feel interested in this field, but still pause before committing. That hesitation makes sense....
Drug Research
Amgen Eyeing Preclinical Blood Cancer Program to Its Skills
Amgen is going ahead and adding Dark Blue to its tapestry, embedding the preclinical blood cancer program of U.K. biotech into its organization.
The California pharma has gone ahead and stitched together a deal of almost $840 million for Dark Blue Therapeutics, which is...
Business & Industry
Daiichi Eyes Commercialization of its Leukemia Med Vanflyta
Daiichi Sankyo is now looking out for new horizons when it comes to its leukemia med Vanflyta, with Genesis Pharma signing to commercialize the drug across certain European countries.
This exclusive license, as well as the supply agreement goes on to...
Clinical Trials
B-Well 1 And B-Well 2 Phase III Trials Fare Well from GSK
GSK plc has announced positive results coming from its two pivotal phase III trials - the B-Well 1 and B-Well 2 phase III trials, assessing bepirovirsen, which is an investigational antisense oligonucleotide - ASO used for the treatment of...
Business & Industry
InduPro, Lilly Partner to Discover Novel Cancer Treatments
Shortly after going ahead and securing a partnership with Sanofi, InduPro is now linking up with Eli Lilly in its endeavors to discover novel cancer treatments through a pact that could as well be worth almost $950 million.
InduPro is...
Business & Industry
Nimbus, Lilly Ink Licence Agreement on Treatments in Obesity
Nimbus Therapeutics has announced that it has entered into a multi-year research partnership and a $1.3 billion exclusive license agreement with Eli Lilly in order to develop oral treatments in obesity as well as other metabolic diseases.
Lilly, which very...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.